Androgen replacement therapy for hypogonadism in advanced cancer patients

Androgen replacement therapy for hypogonadism in advanced cancer patients - ART for advanced cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010939

Enrollment

100

Registered

2013-06-12

Start date

2013-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypogonadism in avanced cancer

Interventions

Enarmon depot intramuscular injection 250mg a month control

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. male 2. pathologically diagnosed as cancer or sarcoma 3. no aplication for radical treatment because of locally advanced or metastatic disease 4. patients know their diagnosis and status 5. obtained informed concent by document 6. normal cardiovascular, hepatic and renal function, and AST(GOT) and ALT(GPT):<3.0 times of institutional upper limit, BUN:<30mg/dL, and Cr:<3.0mg/dL

Exclusion criteria

Exclusion criteria: 1. lrss than 20 year-old 2. prostate cancer or severe BPH 3. PSA>4ng/ml and patients who were thought as inadequate for this study by doctor in charge

Design outcomes

Primary

Measure	Time frame
Comparison of QOL beween control group and ART group	—

Countries

Japan

Contacts

Public ContactKouji Izumi

the Institutional Review Board of Kanazawa University Department of Urology

azuizu2003@yahoo.co.jp0762652019

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026